BioTuesdays

RNA Disease Diagnostics stepwise protocol for molecular diagnosis of COVID-19 published in Nature Protocols

RNA Disease Diagnostics’ stepwise protocol for an RNA-extraction-free nano-amplified colorimetric test for COVID-19 was published in Nature Protocols

The test uses a unique dual-pronged molecular sensing approach that integrates nucleic acid amplification and plasmonic sensing to rapidly detect SARS-CoV-2 in point-of-care settings.

“Our molecular sensing test offers a low-cost, rapid method of screening for COVID-19, with minimal instrumentation, making it ideal for use in a variety of settings, and particularly in places with limited resources,” Allan Oberman, co-founder and chairman of closely-held RNA Disease Diagnostics, said in a statement.

He said the test can easily be adapted to diagnose other infectious diseases. The readout of the test can be monitored using a handheld optical reader to obtain a quantitative response, so “we anticipate this protocol will be widely used to develop biosensors for molecular diagnostics more broadly.”

The RNA-extraction-free nano-amplified colorimetric test uses plasmonic gold nanoparticles capped with antisense oligonucleotides to detect the amplified nucleic acid from SARS-CoV-2, the virus that causes COVID-19, Mr. Oberman said. 

The antisense oligonucleotides are specific for the SARS-CoV-2 N-gene, and when they bind to their target sequence the plasmonic gold nanoparticles aggregate. This highly specific agglomeration step leads to a change in the plasmonic response of the nanoparticles, he added.

The Nature Protocols publication, authored by researchers at the University of Maryland, can be accessed here

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.